USAEUROPEViVE
ABOUTSPONSORSHIPFOUNDATION
Logo Hlth
Logo Hlth
03 Nov 2022 | 03:45 PM GMT

Physician Adoption of Prescription DTx

Anchored by:

Kal Patel, MD
CEO and Co-Founder
BRIGHTINSIGHT

Participants:

Kal Patel, MD CEO and Co-FounderBrightInsight
Kal Patel, MD
CEO and Co-FounderBrightInsight
Kevin Darcy Director, Link StrategyVeeva
Kevin Darcy
Director, Link StrategyVeeva
Anna-Maria Heidinger Head of Digital Innovation HubDaiichi Sankyo Europe
Anna-Maria Heidinger
Head of Digital Innovation HubDaiichi Sankyo Europe
Iman Ahmed Senior Director, Strategic InitiativesOtsuka Precision Health, Inc.
Iman Ahmed
Senior Director, Strategic InitiativesOtsuka Precision Health, Inc.
Joanna Kemp Digital Health Lead - HematologyBristol Myers Squibb
Joanna Kemp
Digital Health Lead - HematologyBristol Myers Squibb
Julia Häring Global Director Digital Health CommercialNovo Nordisk
Julia Häring
Global Director Digital Health CommercialNovo Nordisk
Nina Bufi Lead, BDH Ventures, Digital Therapeutics EUBiogen
Nina Bufi
Lead, BDH Ventures, Digital Therapeutics EUBiogen
Rich DeNunzio Chief Commercial OfficerClick Therapeutics
Rich DeNunzio
Chief Commercial OfficerClick Therapeutics

About this Meeting

Physician adoption is one of the keys to unlocking the revenues expected from DTx solutions. While we have seen immense growth in the DTx market in recent years, physician adoption still remains quite low. Even with the introduction of frameworks like DiGA in Germany, mHealthBelgium, or the RTM codes in the US, significant investments and creativity in marketing and sales models are still needed.  

Join us in a peer-to-peer conversation to discuss the following with other senior leaders:
 
  • Traditional awareness and education strategies have not worked yet in DTx. What innovative and ingenious education strategies can we use when targeting physicians?   
  • From a sales perspective, what alternatives do DTx companies have other than the traditional salesperson model? Would a consultant-like model work better?  
  • How can DTx companies identify early adopters physicians? What are the ‘personas’ they should spend the sales and marketing resources on? 
  • How can digital health formularies, prescription platforms, and rating systems increase the number of prescriptions of DTx by physicians?  
  • The importance of showing that the DTx can be seamlessly integrated into physicians’ daily routine without friction. How can we do this efficiently? How can DTx companies build more physician-friendly solutions while being patient-centric too? 
  • Do we need health systems and hospitals to be the primary buyer so that they mandate changes to physicians? 

We would like to remind you that our meetings are small and intimate sessions with a limited number of seats available, therefore we rely on your attendance and participation to ensure a high quality and valuable meeting for all. If you are confirmed for this meeting we ask if you can please ensure your attendance on the day.